AR062596A1 - Composicion farmaceutica liquida estabilizada para prevencion y/o tratamiento de diversas enfermedades metabolicas oseas como osteopatias metabolicas, proceso de preparacion de dicha composicion y uso de la composicion para preparar un medicamento - Google Patents

Composicion farmaceutica liquida estabilizada para prevencion y/o tratamiento de diversas enfermedades metabolicas oseas como osteopatias metabolicas, proceso de preparacion de dicha composicion y uso de la composicion para preparar un medicamento

Info

Publication number
AR062596A1
AR062596A1 ARP070103850A ARP070103850A AR062596A1 AR 062596 A1 AR062596 A1 AR 062596A1 AR P070103850 A ARP070103850 A AR P070103850A AR P070103850 A ARP070103850 A AR P070103850A AR 062596 A1 AR062596 A1 AR 062596A1
Authority
AR
Argentina
Prior art keywords
composition
gum
metabolic
prevention
prepare
Prior art date
Application number
ARP070103850A
Other languages
English (en)
Inventor
Liliana Elisabeth Diaz
Original Assignee
Gador Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gador Sa filed Critical Gador Sa
Publication of AR062596A1 publication Critical patent/AR062596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con una composicion farmacéutica liquida estabilizada para prevencion y/o tratamiento de diversas enfermedades metabolicas oseas como osteopatías metabolicas, un proceso de preparacion de dicha composicion y uso de la composicion para preparar un medicamento. La citada composicion comprende, entre otros a) un principio activo ácido alendronico o sus sales farmacéuticas aceptables, b) un agente aumentador de la viscosidad seleccionado entre alginato, propilglicolalginato, goma arábiga (acacia) goma xántrica, goma guar, locust beam, goma carragenina, goma Baraya, goma tragacanto, quitosan y carbomer o mezclas de estos, d) un agente saborizante capaz de proporcionar un sabor y un aspecto frutal a la composicion, especialmente saborizante a naranja, y d) un agente colorante capaz de contribuir al aspecto frutal de la composicion e) agua purificada. Debido a que en la presente la composicion presenta un aspecto de jugo de frutas, es más simple recordar cuando debe ingerirse la composicion, ya que se la puede asociar con una bebida e ingerir antes de las comidas, con lo que se supera el fracaso terapéutico que tiene lugar con frecuencia cuando las personas olvidan ingerir los bisfosfonatos o los ingieren en el momento inadecuado
ARP070103850A 2006-09-04 2007-08-30 Composicion farmaceutica liquida estabilizada para prevencion y/o tratamiento de diversas enfermedades metabolicas oseas como osteopatias metabolicas, proceso de preparacion de dicha composicion y uso de la composicion para preparar un medicamento AR062596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06018423A EP1894557B1 (en) 2006-09-04 2006-09-04 Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore

Publications (1)

Publication Number Publication Date
AR062596A1 true AR062596A1 (es) 2008-11-19

Family

ID=37440291

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103850A AR062596A1 (es) 2006-09-04 2007-08-30 Composicion farmaceutica liquida estabilizada para prevencion y/o tratamiento de diversas enfermedades metabolicas oseas como osteopatias metabolicas, proceso de preparacion de dicha composicion y uso de la composicion para preparar un medicamento

Country Status (14)

Country Link
EP (1) EP1894557B1 (es)
AR (1) AR062596A1 (es)
AT (1) ATE498391T1 (es)
AU (1) AU2007294261B2 (es)
CL (1) CL2007002514A1 (es)
CY (1) CY1111202T1 (es)
DE (1) DE602006020137D1 (es)
DK (1) DK1894557T3 (es)
ES (1) ES2361333T3 (es)
MY (1) MY148248A (es)
PL (1) PL1894557T3 (es)
PT (1) PT1894557E (es)
SI (1) SI1894557T1 (es)
WO (1) WO2008028547A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103191414B (zh) * 2013-03-29 2014-10-22 武汉中博绿亚生物科技有限公司 一种宠物快速吸收的液体钙及其制备方法
CN116616449A (zh) * 2023-06-05 2023-08-22 浙江索契壹营养科技有限公司 一种酸性抗菌体系稳定承载高钙和维生素d的饮液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
MXPA03006565A (es) * 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.

Also Published As

Publication number Publication date
EP1894557B1 (en) 2011-02-16
PT1894557E (pt) 2011-03-02
CL2007002514A1 (es) 2008-01-11
SI1894557T1 (sl) 2011-04-29
ATE498391T1 (de) 2011-03-15
CY1111202T1 (el) 2015-06-11
DK1894557T3 (da) 2011-05-30
DE602006020137D1 (de) 2011-03-31
AU2007294261B2 (en) 2012-09-06
EP1894557A1 (en) 2008-03-05
MY148248A (en) 2013-03-29
AU2007294261A1 (en) 2008-03-13
PL1894557T3 (pl) 2011-07-29
ES2361333T3 (es) 2011-06-16
WO2008028547A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
Abad et al. Effect of Matricaria chamomilla hydroalcoholic extract on cisplatin-induced neuropathy in mice
MX2017011280A (es) Terapia neuro-afectiva regional topica con cannabinoides.
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
UY30321A1 (es) Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones
BRPI0910341A8 (pt) dispositivo para conservação, preparação espontanea e administração de um principio ativo
US20130150658A1 (en) Intra-nasal Aromatherapy Clip
CL2007001018A1 (es) Inhalador para administrar un medicamento en forma de sustancias inhalables, formulaciones o mezclas de sustancias, comprende una carcasa que presenta un interior para lojar el medicamento, la carcasa esta unida de forma fija a una boquilla, ademas puede incorporar una aguja para perforar una capsula con medicamento.
WO2007135578A3 (en) Warning system for timely administration of drugs that have to be administered at certain times
BR112014012522A2 (pt) método para encher um reservatório, reservatório e conjunto para encher um reservatório
AR035652A1 (es) Una composicion nutricional, util para combatir la infeccion en el tracto gastrointestinal causada por organismos tipo helicobacter, el uso de dicha composicion para la preparacion de medicamentos, o productos alimenticios y el procedimiento para preparar dicha composicion
Mercadante Management of cancer pain
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
TW200740424A (en) Taste masking dosage form
AR062596A1 (es) Composicion farmaceutica liquida estabilizada para prevencion y/o tratamiento de diversas enfermedades metabolicas oseas como osteopatias metabolicas, proceso de preparacion de dicha composicion y uso de la composicion para preparar un medicamento
BR112017022984A2 (pt) dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente
DK3142651T3 (en) PHARMACEUTICAL SOLUTION CONTAINING DOPAMINE FOR USE TO TREAT PARKINSON'S DISEASE
BR112018016287A2 (pt) sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão
AR076916A1 (es) Medicamento a base de calcio y de vitamina d. kit.
AR084298A1 (es) Comprimido farmaceutico orodispersable a base de zolpidem
Agarwal Effectiveness of low-dose oral calcium carbonate for the prevention of citrate-related toxicity in peripheral blood stem cell collection
岑超 et al. The Comparison of 2 New Promising Weapons for the Treatment of Hydatid Cyst Disease: PAIR and Laparoscopic Therapy
WO2021198739A1 (en) Novel medicinal compound for combating viral infections like corona virus infection and method of mitigating the conditions
Weiler Sumatriptan/venlafaxine
LeRoith Insulin therapy. Foreword
WO2010065291A3 (en) Flavored supplements in liquid form to be added to food and methods of using same

Legal Events

Date Code Title Description
FB Suspension of granting procedure